Ultralente Insulin

06/01/2002 - "In the "Diabetes Prevention Trial-Type 1", the prophylactic subcutaneous administration of low-dose ultralente insulin was not able to prevent the development of type 1 diabetes nor to preserve residual insulin secretion in young relatives at very high-risk of diabetes, selected upon genetic, immunological and metabolic criteria. "
06/01/2002 - "Attempt at preservation of B cells during the initial phase of type 1 diabetes: negative results with ultralente insulin, but promising results with an anti-CD3 monoclonal antibody]."
08/01/2005 - "We performed a secondary analysis of the parenteral arm of the Diabetes Prevention Trial-Type 1 Diabetes (DPT-1), a randomized controlled trial of low-dose parenteral insulin (human ultralente insulin at 0.25 units x kg(-1) x day(-1)) in subjects with a >50% 5-year risk of diabetes. "
01/01/2005 - "Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes."
11/01/1991 - "We postulated that substituting human ultralente insulin for the presupper dose of intermediate-acting insulin would improve overnight glycemic control in children and adolescents with IDDM. "

04/01/1997 - "To study this, groups of rats were injected with approximately 25 U/kg ultralente insulin daily at 1700 for 8 days to maintain hypoglycemia. "
05/01/1991 - "Groups of 8 male Wistar rats were injected with ultralente insulin (20-60 U/kg) to induce either acute hypoglycemia (7 h after a single injection) or chronic hypoglycemia (8 days with daily injections). "
11/01/2000 - "To directly compare the rate of hypoglycemia and metabolic control achieved on once-daily ultralente insulin administration with twice-daily NPH insulin administration in patients with type 2 diabetes. "
02/01/1996 - "In an infant with transient neonatal diabetes mellitus, control of the blood glucose concentration was attained with ultralente insulin treatment, without any episodes of hypoglycemia. "
09/01/2002 - "Clinical trials indicate that insulin glargine is at least as effective as NPH insulin and ultralente insulin, and is associated with a reduced risk of nocturnal hypoglycemia. "

07/01/1999 - "Diabetic rats received daily ultralente insulin to maintain moderate hyperglycemia ( approximately 18 mM). "
06/01/1992 - "Recently, the use of bedtime NPH or ultralente insulin has been emphasized for control of moderate hyperglycemia in these patients. "
04/01/1989 - "Diabetic rats received daily ultralente insulin to maintain moderate hyperglycemia (approximately 300 mg/dl). "
06/01/1986 - "Diabetic rats received daily ultralente insulin to maintain stable moderate hyperglycemia (approximately 350 mg/dl). "
06/01/1994 - "Improvement of basal hepatic glucose production and fasting hyperglycemia of type I diabetic patients treated with human recombinant ultralente insulin."

11/01/2000 - "A crossover study was performed involving five centers and 79 patients with type 2 diabetes (fasting blood glucose > 8 mmol/l) with a 2-month run-in followed by two 6-month periods of either NPH or ultralente insulin administration. "
06/01/1996 - "[Comparative study of the efficiency of ultralente insulin and NPH insulin combined with sulfonylurea in type 2 diabetes patients with secondary tolerance to sulfonylurea. "
01/01/1987 - "A randomized crossover study of 5-g guar minitablets against placebo, given three times per day with main meals for 8 wk, was done in 29 non-insulin-dependent diabetes mellitus (NIDDM) patients who had near-normal fasting plasma glucose concentrations on treatment with diet alone, additional sulfonylurea, or ultralente insulin. "
10/01/1997 - "Eight subjects with NIDDM underwent three 8-week periods in a randomized crossover design of therapy with diet alone, sulfonylurea (gliclazide), or insulin (ultralente). "
07/01/1990 - "Combined therapy with glibenclamide and ultralente insulin in lean patients with NIDDM with secondary failure of sulfonylureas. "

02/01/1996 - "Ultralente insulin treatment of transient neonatal diabetes mellitus."
06/15/1992 - "Use of ultralente insulin in cats with diabetes mellitus."
06/01/1995 - "Ultralente insulin has replaced protamine zinc insulin as the treatment of choice in treatment of diabetes mellitus in cats. "
02/01/1996 - "In an infant with transient neonatal diabetes mellitus, control of the blood glucose concentration was attained with ultralente insulin treatment, without any episodes of hypoglycemia. "
02/01/1996 - "We recommend subcutaneous injection of ultralente insulin, rather than lente or isophane (NPH) insulin, to avoid hypoglycemia during the treatment of transient neonatal diabetes mellitus."